SINTX TechnologiesSINT +1.18%27 Debt-to-EBITDA is -0.31 as of Mar. 2026. GuruFocus rates SINT with a GF Score™ of 27/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 468 Medical Devices & Instruments companies, SINTX Technologies ranks worse than 213675% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for SINTX Technologies's Debt-to-EBITDA or its related term are showing as below:
SINT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.84 Med: -0.34 Max: -0.02
Current: -0.32
During the past 13 years, the highest Debt-to-EBITDA Ratio of SINTX Technologies was -0.02. The lowest was -0.84. And the median was -0.34.
SINT's Debt-to-EBITDA is ranked worse than 100% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs SINT: -0.32
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SINTX Technologies Debt-to-EBITDA Related Terms
SINTX Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for SINTX Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SINT vs ALRTF, CODX, PMI: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, SINTX Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SINTX Technologies Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SINTX Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
SINTX Technologies (SINT) has a Debt-to-EBITDA of -0.31 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SINTX Technologies. According to the industry distribution chart, SINTX Technologies ranks #999999 out of 468 companies in the Medical Devices & Instruments industry.
Is SINTX Technologies' Debt-to-EBITDA too high?
SINTX Technologies' current Debt-to-EBITDA is -0.31. Based on the distribution chart, SINTX Technologies ranks #999999 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, SINTX Technologies has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SINTX Technologies' Debt-to-EBITDA compare to ALRTF and CODX?
According to the Medical Devices & Instruments industry distribution chart, SINTX Technologies ranks #999999 out of 468 companies for Debt-to-EBITDA. This places SINTX Technologies in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SINTX Technologies. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SINTX Technologies's current Debt-to-EBITDA is -0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SINTX Technologies stock overvalued right now?
Based on GuruFocus' analysis, SINTX Technologies (SINT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.72 — trading 1046.7% above its estimated fair value. The current Debt-to-EBITDA is -0.31. SINTX Technologies' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For SINTX Technologies (SINT), the current Debt-to-EBITDA is -0.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SINTX Technologies (SINT) Overvalued in 2026?
Based on GuruFocus' analysis, SINTX Technologies stock appears to be overvalued.
The current stock price of $1.72 is trading 1046.7% above its estimated GF Value™ of $0.15.
GuruFocus considers SINTX Technologies to be Significantly Overvalued.
Key valuation signals for SINT:
Debt-to-EBITDA: -0.31
GF Value™: $0.15 vs. price of $1.72 (1046.7% above fair value)
No single metric tells the full story. See the SINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
27GF Score
Get the complete analysis for SINT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SINT has been successfully added to your 
